Share this article on:

Examination of Serum miRNA Levels in Kidney Transplant Recipients With Acute Rejection

Betts, Gareth; Shankar, Sushma; Sherston, Sam; Friend, Peter; Wood, Kathryn J.

doi: 10.1097/
Letters to the Editor

Transplantation Research Immunology Group Nuffield Department of Surgical Sciences University of Oxford John Radcliffe Hospital Oxford, UK

This work was supported by a grant from the Wellcome Trust.

The authors declare no conflicts of interest.

Address correspondence to: Gareth Betts, Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK.


Received 8 August 2013.

Accepted 6 November 2013.

MiRNAs inhibit translation of messenger RNAs and are highly stable in serum (1, 2) and urine (3), making them potential biomarkers of pathology, including rejection of solid organ allografts (4–8).

miR-10a, -10b, 30c, 32, 142-3p, -223, and let-7c (4, 9) are differentially expressed in allograft biopsies undergoing acute rejection (AR) in kidney transplant recipients (KTRs) compared with healthy allograft biopsies, as is miR-483 compared with nontransplanted kidney (10). miR-30c, 32, -142-3p, -204, -211, -223, -483, and -663b are differentially expressed in KTR biopsies with interstitial fibrosis/tubular atrophy (IF/TA) compared with healthy allografts (11, 12). miR 142-3p, -204, and -211 in KTRs with IF/TA (12) and miR-10a and -10b in KTRs with acute rejection (3) was differentially expressed in urine compared with stable KTRs. Several miRNA are elevated in patient serum during acute rejection of liver (2) and heart allografts (13).

Twelve KTRs receiving basiliximab, tacrolimus, and steroids, with azathioprine or mycophenolate mofetil, were enrolled (REC number 07/H0603/26). All patients were negative for donor-specific antibodies (DSA) pretransplantation and so did not receive pretransplant desensitization. All patients had primary renal function after transplant. Seven of these patients underwent a single biopsy proven acute cellular rejection (AR) within the first year posttransplantation and an additional patient at day 404 posttransplant. All biopsies were scored according to the Banff criteria: three biopsies scored 4 IA, one biopsy scored 4 IIA, one biopsy scored 4 IIB, and three biopsies scored 3. All biopsies were C4d negative. Each AR episode was successfully treated with three daily doses of 500-mg methylprednisolone, as measured by restored eGFR to baseline, posttreatment. The remaining four patients maintained healthy graft function throughout and were matched for HLA, race, induction and maintenance therapy, and initial graft function to patients with AR. There was no difference in PRA between control and AR groups. All 12 patients maintained healthy graft function and eGFR at baseline at 1 year posttransplantation. Within the AR group, miRNA levels were measured at several time points: PRE-AR, AR, POST-AR, and 1 year posttransplantation. MiRNA levels in the control group were measured at time points parallel to those of AR patients at time of AR. We hypothesized that miRNAs demonstrated to be differentially expressed in biopsy material, and urine of KTRs undergoing rejection is also differently expressed in serum; we therefore analyzed the expression of several candidate miRNAs (Fig. 1). mirVana PARIS kit was used to purify RNA from KTR serum archived at −40°C before RT, preamplification, and qPCR (Life Technologies).



There was a significant reduction of miR-223 and miR-10a levels (P<0.05) and a trend for reduced miR-30c, miR-142-3p, and miR-483 levels (P=0.063) in serum 1 year posttransplant compared with the AR samples, whereas Let-7c, miR-10b, miR-204, and miR-663 levels were not different (Fig. 1). Interestingly, there was no difference in the expression of any miRNA measured between AR and control samples (Fig. 1). AR episodes occurred soon after transplant, with 3/8 AR within a week and two more within 50 days of transplant. It is possible that the difference between AR and 1 year samples is due to a decrease in serum miRNA levels at a greater interval since transplant, independently of AR. The number of PRE-AR samples available was too low to provide conclusive results, but an elevated expression of miR-223 and miR-10a compared with 1-year samples, independent of AR, is indicated (Fig. 1). Analysis of AR and POST-AR samples (mean POST-AR =174 days posttreatment) suggests levels began to reduce closer to the date of the transplant, with a trend for reduced levels of miR-223 and miR-10a (P=0.063). A similar trend of reduced miR-204 level was observed POST-AR compared with AR (P=0.063). The miR-204 level was significantly higher in controls, measured shortly after transplantation, compared with 1 year after transplant in KTRs that had an AR episode (P<0.05), highlighting the possibility that miRNA expression levels observed 1 year posttransplant might fall independently of an AR episode.

Examination of control patients early posttransplant and at 1 year posttransplant could elucidate whether reduced miR-223 and miR-10a levels with extended time posttransplant are associated with factors independent of AR, including longer exposure to posttransplant maintenance immunosuppression.

These data have to be interpreted cautiously because of the small patient cohort. It seems that miRNA levels in kidney biopsies and urine previously described to be differentially expressed in healthy allografts and those undergoing rejection are not universally translated to differential expression in the serum. These data also indicate that miRNA levels alter after transplantation, independently of AR, highlighting the importance of carefully matching cohorts of KTRs with healthy allografts and AR.

Gareth Betts

Sushma Shankar

Sam Sherston

Peter Friend

Kathryn J. Wood

Transplantation Research Immunology Group

Nuffield Department of Surgical Sciences

University of Oxford

John Radcliffe Hospital

Oxford, UK

Back to Top | Article Outline


The authors thank Sally Ruse for phlebotomy and organizing patient logistics.

Back to Top | Article Outline


1. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997.
2. Farid WR, Pan Q, van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012; 18: 290.
3. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11: 2221.
4. Anglicheau D, Muthukumar T, Suthanthiran M. MicroRNAs: small RNAs with big effects. Transplantation 2010; 90: 105.
5. Harris A, Krams SM, Martinez OM. MicroRNAs as immune regulators: implications for transplantation. Am J Transplant 2010; 10: 713.
6. Heidt S, San Segundo D, Shankar S, et al. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011; 92: 1.
7. Mas VR, Dumur CI, Scian MJ, et al. MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant 2013; 13: 11.
8. Wilflingseder J, Regele H, Perco P, et al. miRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation 2013; 95: 835.
9. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009; 106: 5330.
10. Sui W, Dai Y, Huang Y, et al. Microarray analysis of MicroRNA expression in acute rejection after renal transplantation. Transpl Immunol 2008; 19: 81.
11. Ben-Dov IZ, Muthukumar T, Morozov P, et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012; 94: 1086.
12. Scian MJ, Maluf DG, David KG, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011; 11: 2110.
13. Sukma Dewi I, Torngren K, Gidlof O, et al. Altered serum miRNA profiles during acute rejection after heart transplantation: potential for non-invasive allograft surveillance. J Heart Lung Transplant 2013; 32: 463.
© 2014 by Lippincott Williams & Wilkins